Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment

Colloids and Surfaces B: Biointerfaces

Volumn 145, Issue , 2016, Pages 8-13

  Loureiro, Joana A ^a   Gomes, Bárbara ^a   Fricker, Gert ^b   Coelho, Manuel A N ^a   Rocha, Sandra ^c   Pereira, Maria Carmo ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Alzheimer's disease; Antibodies; Blood brain barrier; Drug delivery systems; Immuno nanoparticles; Therapeutic peptides

Indexed keywords

BLOOD; DRUG DELIVERY; ENDOTHELIAL CELLS; MONOCLONAL ANTIBODIES; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEINS;

ALZHEIMER'S DISEASE; ANTI-TRANSFERRIN RECEPTORS; BLOOD-BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELLS; CONTROLLED DELIVERY; DRUG DELIVERY SYSTEM; POLY(LACTIC-CO-GLYCOLIC ACID); THERAPEUTIC PEPTIDES;

ANTIBODIES;

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DE2B4; MONOCLONAL ANTIBODY OX26; NANOCARRIER; PEPTIDE; PEPTIDE IABETA5; POLYGLACTIN; POLYGLACTIN MONOCLONAL ANTIBODY DE2B4; POLYGLACTIN MONOCLONAL ANTIBODY OX26; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; AMYLOID; ANTIBODY; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; DIALYSIS; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; HYDRODYNAMICS; IN VITRO STUDY; NANOENCAPSULATION; NONHUMAN; PIG; PRIORITY JOURNAL; TOXICITY ASSAY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMISTRY; METABOLISM;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; ANTIBODIES; BLOOD-BRAIN BARRIER; BRAIN; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID; RECEPTORS, TRANSFERRIN; SWINE;

EID: 84964562590     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.04.041     Document Type: Article

References (58)

1. Begley D.J., Brightman M.W. Structural and functional aspects of the blood-brain barrier. Prog. Drug Res. 2003, 61:39-78.
2. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38(6):323-337.
3. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2(1):3-14.
4. Pardridge W.M. Drug and gene delivery to the brain: the vascular route. Neuron 2002, 36(4):555-558.
5. Lindqvist A., et al. Enhanced brain delivery of the opioid peptide DAMGO in glutathione PEGylated liposomes: a microdialysis study. Mol. Pharm. 2013, 10(5):1533-1541.
6. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004, 104(1):29-45.
7. de Boer A.G., Gaillard P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 2007, 47:323-355.
8. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47(1):65-81.
9. Ulbrich K., et al. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 2009, 71(2):251-256.
10. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006, 1(3):297-315.
11. Wohlfart S., Gelperina S., Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release 2012, 161(2):264-273.
12. Loureiro J.A., et al. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. Nanomedicine (Lond.) 2014, 9(5):709-722.
13. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7(1):41-53.
14. Calvo P., et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 2001, 18(8):1157-1166.
15. Cerletti A., et al. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J. Drug Target. 2000, 8(6):435-446.
16. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
17. Clippingdale A.B., Wade J.D., Barrow C.J. The amyloid-beta peptide and its role in Alzheimer's disease. J. Pept. Sci. 2001, 7(5):227-249.
18. Calhoun M.E., et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(24):14088-14093.
19. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8(2):101-112.
20. Melnikova I. Therapies for alzheimer's disease. Nat. Rev. Drug Discov. 2007, 6(5):341-342.
21. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256(5054):184-185.
22. Hardy J., Selkoe D.J. Medicine - The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
23. Kirschner D.A., Abraham Selkoe C.D.J. X-Ray-Diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in alzheimer-Disease indicates cross-Beta conformation. Proc. Natl. Acad. Sci. U.S.A. 1986, 83(2):503-507.
24. Selkoe D.J. Presenilins, beta-amyloid precursor protein and the molecular basis of Alzheimer's disease. Clin. Neurosci. Res. 2001, 1(1-2):91-103.
25. Haass C., Selkoe D.J. Cellular processing of beta-Amyloid precursor protein and the genesis of amyloid beta-Peptide. Cell 1993, 75(6):1039-1042.
26. Kang J., et al. The precursor of alzheimers-Disease amyloid-A4 protein resembles a cell-Surface receptor. Nature 1987, 325(6106):733-736.
27. Weidemann A., et al. Identification: biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989, 57(1):115-126.
28. Ladiwala A.R., et al. Conformational differences between two amyloid beta oligomers of similar size and dissimilar toxicity. J. Biol. Chem. 2012, 287(29):24765-24773.
29. Rocha S., et al. Peptide-surfactant interactions: consequences for the amyloid-beta structure. Biochem. Biophys. Res. Commun. 2012, 420(1):136-140.
30. Murphy R.M. Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng. 2002, 4:155-174.
31. Yang M., Teplow D.B. Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. J. Mol. Biol. 2008, 384(2):450-464.
32. Loureiro J.A., et al. Design of potential therapeutic peptides and carriers to inhibit amyloid beta peptide aggregation. Ieee 2nd Portuguese Meeting in Bioengineering (Enbeng), 2012 2012.
33. Levine H. Small molecule inhibitors of A beta assembly. Amyloid-J. Protein Fold. Dis. 2007, 14(3):185-197.
34. Loureiro J.A.S.Rocha, and M.D.Pereira Charged surfactants induce a non-fibrillar aggregation pathway of amyloid-beta peptide. J. Pept. Sci. 2013, 19(9):581-587.
35. Mason J.M., et al. Design strategies for anti-amyloid agents. Curr. Opin. Struct. Biol. 2003, 13(4):526-532.
36. Loureiro J.A., et al. Fluorinated beta-sheet breaker peptides. J. Mater. Chem. B 2014, 2(16):2259-2264.
37. Hilbich C., et al. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol. 1992, 228(2):460-473.
38. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32(18):4693-4697.
39. Soto C., et al. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. 1996, 226(3):672-680.
40. Chou P.Y., Fasman G.D. Empirical predictions of protein conformation. Annu. Rev. Biochem. 1978, 47:251-276.
41. Wood S.J., et al. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry 1995, 34(3):724-730.
42. Schnyder A., et al. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem. J. 2004, 377(Pt. 1):61-67.
43. Bobilya D.J., D'Amour K., Palmer A., Skeffington C., Therrien N., Tibaduiza E.C. Isolation and cultivation of porcine brain capillary endothelial cells as an in vitro model of the blood-brain barrie. Methods Cell Sci. 1995, 17(1):25-32.
44. Hermanson G.T. Bioconjugate Techniques 1996, xxv:785. Academic Press, San Diego.
45. Markoutsa E., et al. Anti-Abeta-MAb and dually decorated nanoliposomes: effect of Abeta1-42 peptides on interaction with hCMEC/D3 cells. Eur. J. Pharm. Biopharm. 2012, 81(1):49-56.
46. Frasco M.F., et al. Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells. J. Biomed. Mater. Res. A 2014.
47. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control Release 2008, 130(2):98-106.
48. Santander-Ortega M.J., et al. Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J. Colloid Interface Sci. 2006, 302(2):522-529.
49. Pardridge W.M., Boado R.J., Kang Y.S. Vector-mediated delivery of a polyamide (peptide) nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(12):5592-5596.
50. Henry N., Parce J.W., McConnell H.M. Visualization of specific antibody and C1q binding to hapten-sensitized lipid vesicles. Proc. Natl. Acad. Sci. U. S. A. 1978, 75(8):3933-3937.
51. Markoutsa E., et al. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur. J. Pharm. Biopharm. 2011, 77(2):265-274.
52. Mason J.M., et al. Design strategies for anti-amyloid agents. Curr. Opin. Struct. Biol. 2003, 13(4):526-532.
53. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 2010, 75(1):1-18.
54. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials 1996, 17(2):103-114.
55. Ford Versypt A.N., Pack D.W., Braatz R.D. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres-a review. J. Control. Release 2013, 165(1):29-37.
56. Mattu C., et al. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells. Eur. J. Pharm. Biopharm. 2013, 85(3 Pt A):463-472.
57. Vangelder W., et al. Quantification of different transferrin receptor pools in primary cultures of porcine blood-Brain-Barrier endothelial-Cells. J. Neurochem. 1995, 64(6):2708-2715.
58. Loureiro J.A., et al. Dual ligand immunoliposomes for drug delivery to the brain. Colloids Surf. B Biointerfaces 2015, 134:213-219.